Lenvatinib-d4
For research use only. We do not sell to patients. Lenvatinib-d4 Biological Activity:Lenvatinib-d4 (E7080-d4) is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities[2]. Research Area:Cancer Targets:VEGFR|RET|c-Kit|FGFR|PDGFR Related Small Molecules:(Z)-FeCP-oxindole;VEGFR-2-IN-24;BMS-690514;PROTAC VEGFR-2 degrader-2;Henatinib;PI3K/VEGFR2-IN-1;c-Kit-IN-5-1;Flumatinib mesylate;IHMT-TRK-284;RET-IN-18;Ferulic acid-13C3;PDGFRα/FLT3-ITD-IN-2;FGFR-IN-7;PP58;Hydroxytanshinone IIA;Chiauranib;Foretinib;ZM323881 hydrochloride;Zeteletinib;FGFR3-IN-1;Pexidartinib;PTC299;ENMD-2076 Tartrate;Aflibercept Trending products:Recombinant […]